Komori
Muromachi Chemicals (4885) · RiskDropped

Growing Uncertainty in the Business Environment Due to COVID-19

First written in FY2021-Q3. 5 of 13 entries say "Mitigated", first in FY2021. Latest entry: FY2026.

13entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMitigatedFY2023 – FY2024-Q32021: 320212022: 420222023: 420232024: 120242025: 020252026: 12026
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1254 companies write about · 1266 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1280 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026DroppedAnnual report

    「During the fiscal year under review, personal consumption weakened amid the continued impact of rising prices, but corporate earnings and capital investment remained firm. Supported by investment demand centered on AI-related and semiconductor fields, the economy maintained a moderate recovery trend.」

    The discussion of the economic environment for the fiscal year under review contains no mention of COVID-19, and the previous theme of uncertainty caused by the pandemic is no longer included.
  2. FY2024-Q3MitigatedAnnual report

    「In the international trade environment, restrictions on movement caused by COVID-19 have largely returned to normal, and the Company has also seen an increase in opportunities for direct business discussions through participation in overseas trade shows and travel to and from overseas companies.」

    It explains that restrictions on movement caused by COVID-19 have largely returned to normal, increasing opportunities for direct business discussions at overseas trade shows and with overseas companies.
  3. FY2024-Q1MitigatedAnnual report

    「As COVID-19 was reclassified as a Class 5 infectious disease in May and the transition to a post-COVID environment progressed, Japan's economy recorded a solid recovery during the cumulative first quarter under review, while corporate earnings also improved moderately alongside a recovery in personal consumption.」

    The recovery in the business environment is described against the backdrop of COVID-19's reclassification as a Class 5 infectious disease and the transition to a post-COVID environment.
  4. FY2023MitigatedAnnual report

    「During the fiscal year under review, Japan's economy showed signs of a moderate recovery as restrictions on movement associated with the spread of COVID-19 were eased and economic and social activity normalized.」

    The easing of restrictions on movement and normalization of economic and social activity are described as improving the previous business-environment risks caused by COVID-19.
  5. FY2023-Q3RestatedAnnual report

    「During the cumulative third quarter under review, Japan's economy showed signs of a moderate recovery as economic and social activity normalized through the easing of restrictions on movement and other measures, although the impact of the spread of COVID-19 remained.」

    It continues to explain that, although the impact of COVID-19 remained, economic and social activity was normalizing through the easing of restrictions on movement and other measures.
  6. FY2023-Q2MitigatedAnnual report

    「During the cumulative second quarter under review, Japan's economy showed signs of a moderate recovery as economic and social activity normalized through the easing of restrictions on movement and other measures, although the impact of the spread of COVID-19 remained.」

    Although the impact of the pandemic remained, the easing of restrictions on movement and normalization of economic and social activity indicated an improvement from the previous uncertainty.
  7. FY2023-Q1RestatedAnnual report

    「During the cumulative first quarter under review, Japan's economy gradually moved toward normalization of economic and social activity, with no restrictions on movement imposed despite the spread of infections during the seventh wave of COVID-19.」

    It states that, while infections continued to spread during the seventh wave of the pandemic, economic and social activity was normalizing without restrictions on movement.
  8. FY2022RestatedAnnual report

    「Although economic activity showed signs of normalization due to progress in COVID-19 vaccinations and other factors, the outlook remained uncertain as it was still impossible to foresee the containment of COVID-19, amid the reissuance of states of emergency and other measures due to renewed spread of infections and the emergence of new variants.」

    While economic activity showed signs of normalization, uncertainty over the outlook caused by the pandemic persisted due to the renewed spread of infections, reissuance of the state of emergency and new variants.
  9. FY2022-Q3WorsenedAnnual report

    「During the cumulative third quarter under review, Japan's economy showed signs of a normalization in economic activity due to the spread of COVID-19 vaccinations. However, the rapid spread of infections caused by a new variant, together with the worsening situation in Ukraine, raised concerns about further increases in crude oil prices and prices generally, leaving the outlook uncertain.」

    While economic activity showed signs of normalization, uncertainty over the outlook intensified due to the rapid spread of infections from a new variant and concerns about higher crude oil prices and prices generally caused by the worsening situation in Ukraine.
  10. FY2022-Q2RestatedAnnual report

    「During the cumulative second quarter under review, Japan's economy saw a continued decline in the number of infections, partly due to the spread of COVID-19 vaccinations, and economic activity gradually began to recover. However, the outlook remained uncertain due to surging crude oil prices, rising prices and the emergence of new variants.」

    While the number of infections declined and economic activity began to recover, uncertainty over the outlook persisted due to the emergence of new variants and other factors.
  11. FY2022-Q1WorsenedAnnual report

    「During the cumulative first quarter under review, Japan's economy showed signs of moving toward a resolution of the pandemic, partly due to the spread of COVID-19 vaccinations. However, the number of infections rose again, a state of emergency was reissued in some prefectures, and restrictions on economic activity continued, leaving the outlook uncertain.」

    While vaccinations have supported progress toward containing the pandemic, the renewed increase in infections and reissuance of the state of emergency have kept the external environment uncertain.
  12. FY2021MitigatedAnnual report

    「Some projects were unaffected or performed well, and overall, the impact of the spread of COVID-19 on sales was limited.」

    Although the pandemic caused delays in project progress and a decline in orders, it explains that the overall impact on sales was limited.
  13. FY2021-Q3First statedAnnual report

    「During the cumulative third quarter under review, Japan's economy remained in a difficult situation due to the impact of COVID-19, although signs of a recovery had begun to emerge, partly as a result of various government policies. However, with the number of infections again trending upward, the outlook remained uncertain.」

    The impact of the spread of infection and uncertainty over the outlook due to the renewed increase in cases are cited as external risks.
Moved together

"Results for the nine months ended in the third quarter" moved the same way as this thread, in the same document, in 5 of its 13 moves.

543332★123456
  1. ★This thread
  2. 1Results for the nine months ended in the third quarter5×
  3. 2Increase in Net Assets and Higher Equity Ratio4×
  4. 3Steady sales of core pharmaceuticals and related products3×
  5. 4Executive Compensation Policy Including Restricted Stock3×
  6. 5Revenue Recognition from Large-Scale Equipment Projects and Solid Sales of Chemical Products3×
  7. 6Negative Operating Cash Flow and Decline in Cash Balance2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Muromachi Chemicals yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Growing Uncertainty in the Business Environment Due to COVID-19 | MUROMACHI CHEMICALS INC. (4885) | Komori